drugset
drugset / Trial / NCT04196530

BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab

NCT04196530 ↗

Phase 1 Completed 40 enrolled Eikon Therapeutics Seven and Eight · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

A Phase 1 Open-label Dose Escalation Study of BDB001 in Combination with Atezolizumab in Subjects with Advanced Solid Tumors

Timeline

Start
2019-11-21
Primary completion
2024-07-31
Completion
2024-08-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Resiquimod Small molecule — —
Background Atezolizumab Monoclonal antibody — Intravenous

Indications

No indication recorded.